TY  - BOOK
AU  - DeSimone, Jennifer A
AU  - DiLorenzo, Ashley
AU  - Lindberg, Michael 
TI  - Cutaneous T-Cell Lymphoma Treatment: Case Series of Combination Therapy With Intralesional Injections of 5-Fluorouracil and Topical Imiquimod
SN  - 0011-4162
PY  - 2023///
KW  - *Lymphoma, T-Cell, Cutaneous
KW  - *Skin Neoplasms
KW  - Fluorouracil
KW  - Humans
KW  - Imiquimod/tu [Therapeutic Use]
KW  - Injections, Intralesional
KW  - Lymphoma, T-Cell, Cutaneous/dt [Drug Therapy]
KW  - Skin Neoplasms/pa [Pathology]
KW  - MedStar Washington Hospital Center
KW  - Dermatology
KW  - Medical Dermatology Residency
KW  - Journal Article
N1  - Available online through MWHC library: 2000 - 2010, Available in print through MWHC library: July 1998 - 2007
N2  - Cutaneous T-cell lymphoma (CTCL) is a chronic form of skin cancer. Skin-directed therapies rarely achieve complete clearance of lesions, and recurrences are frequent. In this case series, 9 patients with stage IA to IVA2 CTCL received intralesional (IL) therapy with 5-fluorouracil (5-FU) and imiquimod (IMQ) cream 5% daily to recalcitrant plaques and tumors. All 9 patients attained a complete response (CR) with no recurrences reported and no severe side effects. We find that combination IL 5-FU and IMQ cream 5% daily is a well-tolerated, effective, and durable skin-directed therapy for recalcitrant plaques and tumors in CTCL
UR  - https://dx.doi.org/10.12788/cutis.0697
ER  -